tbuckley/cabot-search huggingface dataset:
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction
Authors: John J.V. McMurray, Alice M. Jackson, Carolyn S.P. Lam, Margaret M. Redfield, Inder S. Anand, Junbo Ge, Marty P. Lefkowitz, Aldo P. Maggioni, Felipe Martinez, Milton Packer, Marc A. Pfeffer, Burkert Pieske, Adel R. Rizkala, Shalini V. Sabarwal, Amil M. Shah, Sanjiv J. Shah, Victor C. Shi, Dirk J. van Veldhuisen, Faiez Zannad, Michael R. Zile, Maja Cikes, Eva Goncalvesova, Tzvetana Katova, Anamaria Kosztin, Malgorzata Lelonek, Nancy Sweitzer, Orly Vardeny, Brian Claggett, Pardeep S. Jhund, Scott D. Solomon
Journal: Circulation (2019)

Background: Unlike heart failure with reduced ejection fraction, there is no approved treatment for heart failure with preserved ejection fraction, the predominant phenotype in women. Therefore, there is a greater heart failure therapeutic deficit in women compared with men. Methods: In a prespecified subgroup analysis, we examined outcomes according to sex in the PARAGON-HF trial (Prospective Comparison of ARNI With ARB Global Outcomes in Heart Failure With Preserved Ejection Fraction), which compared sacubitril-valsartan and valsartan in patients with heart failure with preserved ejection fraction. The primary outcome was a composite of first and recurrent hospitalizations for heart failure and death from cardiovascular causes. We also report secondary efficacy and safety outcomes. Results: Overall, 2479 women (51.7%) and 2317 men (48.3%) were randomized. Women were older and had more obesity, less coronary disease, and lower estimated glomerular filtration rate and NT-proBNP (N-terminal pro–B-type natriuretic peptide) levels than men. For the primary outcome, the rate ratio for sacubitril-valsartan versus valsartan was 0.73 (95% CI, 0.59–0.90) in women and 1.03 (95% CI, 0.84–1.25) in men ( P interaction = 0.017). The benefit from sacubitril-valsartan was attributable to reduction in heart failure hospitalization. The improvement in New York Heart Association class and renal function with sacubitril-valsartan was similar in women and men, whereas the improvement in Kansas City Cardiomyopathy Questionnaire clinical summary score was less in women than in men. The difference in adverse events between sacubitril-valsartan and valsartan was similar in women and men. Conclusions: As compared with valsartan, sacubitril-valsartan seemed to reduce the risk of heart failure hospitalization more in women than in men. Whereas the possible sex-related modification of the effect of treatment has several potential explanations, the present study does not provide a definite mechanistic basis for this finding. Clinical Trial Registration: https://www.clinicaltrials.gov . Unique identifier: NCT01920711.
PRC2 Mutations Induce Resistance to Conventional Chemotherapy By Inhibiting Mitochondrial Apoptosis in T-Cell Acute Lymphoblastic Leukemia
Authors: Ingrid Ariës, Triona Ni Chonghaile, Salmaan Karim, Mina Jacob, Kristen E. Stevenson, Donna S. Neuberg, Meenakshi Devidas, Mignon Loh, Stephen Hunger, David T Teachey, Karen R. Rabin, Stuart S. Winter, Kimberly P. Dunsmore, Brent L. Wood, Lewis B. Silverman, Stephen E. Sallan, Birgit Knoechel, Pieter Van Vlierberghe, Anthony Letai, Alejandro Gutierrez
Journal: Blood (2016)
Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Three Phase III Randomized Controlled Trials
Authors: Sriman Swarup, Donald P. Quick, Anita Sultan, Nicholas D'Cunha, Thura Win Htut, Pwint Phyu Hlaing, Upama Sharma, Nimesh Adhikari, Ye Aung, Myat Min Han, Yin Mon Myat, Fred Hardwicke, Lukman Tijani, Kyaw Zin Thein
Journal: Blood (2019)
Autologous Transplant Recipients Have a Healthier Gut Microbiota at Baseline and Faster Recovery from Microbiome Injury Compared to Allogeneic Transplant Recipients
Authors: Rajat Bansal, Heekuk Park, Cristian Taborda, Christian Gordillo, Markus Y. Mapara, Amer Assal, Anne-Catrin Uhlemann, Ran Reshef
Journal: Blood (2019)
Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel
Authors: Ajeet Gajra, Marjorie E Zettler, Eli G Phillips Jr., Andrew J Klink, Jonathan K. Kish, Sonam Mehta, Bruce Feinberg
Journal: Blood (2019)
A Quantitative Systems Pharmacology (QSP) Model to Predict Receptor Occupancy of Bruton's Tyrosine Kinase (BTK) Inhibitors in Peripheral Blood Mononuclear Cells, Bone Marrow and Lymph Nodes of Patients with B-Cell Malignancies
Authors: Srikumar Sahasranaman, Oleg Demin, Dmitry Shchelokov, Veronika Musatova, Nageshwar Budha, Ying Ou
Journal: Blood (2019)
Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement
Authors: Guillaume Richard-Carpentier, Hagop M. Kantarjian, Guilin Tang, C. Cameron Yin, Joseph D. Khoury, Ghayas C. Issa, Nitin Jain, Farhad Ravandi, Nicholas J. Short, Courtney D. DiNardo, Koichi Takahashi, Maro Ohanian, Gautam M. Borthakur, Marina Y Konopleva, Naval G. Daver, Zeev E. Estrov, Yesid Alvarado, Alessandra Ferrajoli, Tapan M. Kadia, Guillermo Garcia-Manero, Srdan Verstovsek, Rebecca Garris, Jorge E. Cortes, Susan O'Brien, Elias Jabbour
Journal: Blood (2019)
GP to appeal decision that failure to refer patient for heart tests led to spinal injury
Authors: Clare Dyer
Journal: BMJ (2019)

A GP who was found liable for a serious spinal injury sustained by a patient whom he had failed to refer to hospital for tests has applied for permission to take the case to the Court of Appeal.

The High Court ruled that GP Majella Okeahialam was liable for the injury to Tahir Younas, then aged 43, who fell and hit his head after fainting while crossing a car park in January 2014.1 In October 2013 Younas had had an electrocardiogram at the GP’s surgery that showed electrical abnormalities, but the doctor failed to refer him to a hospital cardiology department.

The GP admitted negligence, but a claimant in a clinical negligence case must also prove that the negligence caused the injury. Younas’s lawyers argued …
RTHP-17. APPLICATION OF EXACTRAC X-RAY IMAGE GUIDE SYSTEM IN STEREOTACTIC RADIOSURGERY FOR INTRACRANIAL NEURAL TUMORS IN PATIENTS AGED 3–14 YEARS
Authors: Linbo Cai, Qing Xiao
Journal: Neuro-Oncology (2019)

Abstract OBJECTIVES To investigate the setup accuracy in stereotactic radiosurgery based on Exactrac Xray image guide system for intracranial neural tumors in patients aged between 3 and 14 years, and to discuss the related influence factors. METHODS Thirty seven patients with intracranial neural tumors, at the age of 314 years old, who were admitted to Guangdong Sanjiu Brain Hospital between March 2017 to January 2019 were enrolled in this study. After automatic setup with infrared markers, Exactrac Xray image guide system was applied to obtain the image of bilateral oblique intersection field, which were then registered with the field image digitally reconstructed with planning system, so as to obtain the translational errors in LAT (X), LNG (Y), VRT (Z) directions and the corresponding rotational errors. RESULTS After the positioning with Exactrac Xray image guide system and sixdimensional couch, the translational errors of all 37 patients in LAT, LNG, VRT directions were (0.26±0.13), (0.17±0.13), (0.15±0.11) mm, respectively, and the corresponding rotational errors were 0.21°±0.15°, 0.18°±0.15°, 0.18°±0.14°, respectively. The space vector error was (0.32±0.16) mm; translational errors were all less than 0.5 mm; rotational errors were all less than 0.5°. All of these errors were less than specified values and in accordance with the requirements of SRS. CONCLUSION Using Exactrac Xray image guide system and sixdimensional couch can remarkably improve the accuracy of SRS for intracranial neural tumors in patients aged 314 years. Exactrac Xray image guide system is worthy of application in the clinic.
Clinical Characterization and Cytokine Profile of Fatigue in Patients with Chronic Gvhd
Authors: Sencer Goklemez, Saligan Leorey, Filip Pirsl, Seth M. Steinberg, Sandra A Mitchell, Frances T. Hakim, Jeremy J. Rose, Zhigang Kang, Yunkai Yu, Liang Cao, Annie Im, Steven Z. Pavletic
Journal: Blood (2019)
High Risk DLBCL in Younger Patients: Should ASCT be Declined in the Era Pos-Rituximab?
Authors: Miguel Quintela, Iolanda Vieira, Cláudia Moreira, Sérgio Chacim, Nelson Domingues, Isabel Oliveira, Ana Espirito Santo, Maria Ilidia Moreira, Ângelo Martins, Maria Luisa Viterbo, Dulcineia Pereira, Jose Mario Mariz
Journal: Blood (2019)
Validation of the Revised AML-Composite Model for the Prediction of Prognosis in Older Patients Receiving Intensive Induction Therapy
Authors: Corentin Orvain, Aline Tanguy-Schmidt, Sylvain Thepot, Anne Bouvier, Benedicte Ribourtout, Franck Genevieve, Aurelien Giltat, Marion Champire, Adeline Chanson, Marielle Subileau, Damien Luque Paz, Valerie Ugo, Norbert Ifrah, Mathilde Hunault
Journal: Blood (2019)
PDTM-02. TARGETING THE RB PATHWAY IN MEDULLOBLASTOMA
Authors: Barbara Jonchere, Jennifer Stripay, Allison Pribnow, Frederique Zindy, Jaeki Min, Burgess Freeman, Anang Shelat, Zoran Rankovic, Martine Roussel
Journal: Neuro-Oncology (2019)

Abstract Medulloblastoma (MB), the most common malignant pediatric brain tumor, is classified into four major molecularly and histopathologically distinct subgroups, among which MYC-driven Group 3 MBs confer a poor prognosis. The Cyclin D/CDK4/CDK6/RB pathway is frequently deregulated in MB leading to uncontrolled cell proliferation, but tumors express an intact RB protein (Northcott et al., Nature, 2017). Therefore, CDK4/6 inhibitor drugs offer a possible therapeutic approach to treat MBs. Because single agent therapy ultimately leads to drug resistance, we initiated in vitro combination drug screens to identify drug classes potentiating CDK4/6 inhibitors. We used Group 3 MB patient-derived orthotopic xenografts (PDOXs), a human cell line (HDMB03), and freshly dissociated tumor cells propagated only in the mouse brain. The drug screen included 90 compounds comprising targeted and cytotoxic drugs that are FDA approved or under active clinical investigation. Using a bioluminescence-based assay that measures ATP consumption (CellTiter-Glo) to evaluate the number of viable cells, these 90 compounds were screened in combination with a fixed concentration of ribociclib, one of the three FDA approved CDK4/6 inhibitors. The primary screen, carried out in HDMB03 cells, revealed several drugs with additive or synergistic potential when combined with ribociclib, including BET inhibitors, MEK inhibitors, PI3K/mTOR inhibitors and gemcitabine. We are currently evaluating the combination of brain penetrant compounds in Group 3 MB PDOXs. The identification of potent drug combinations should provide new therapeutic options for the treatment of Group 3 MB, one of the most difficult to treat.
Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
Authors: Lucia Masarova, Srdan Verstovsek, Prithviraj Bose, Naveen Pemmaraju, Jorge E. Cortes, Elias Jabbour, Maro Ohanian, Lingsha Zhou, Sherry A. Pierce, Romany Gergis, Gautam M. Borthakur, Tapan M. Kadia, Courtney D. DiNardo, Farhad Ravandi, Marina Y Konopleva, Kiran Naqvi, Koji Sasaki, Zeev E. Estrov, Guillermo Garcia-Manero, Carlos E. Bueso-Ramos, Hagop M. Kantarjian, Naval G. Daver
Journal: Blood (2019)
Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab
Authors: Spero Cataland, Gema Ariceta, Peter Chen, Bradley Dixon, Katherine Garlo, Laurence Greenbaum, Eric Rondeau, Marie Scully, Stephan Ortiz
Journal: Blood (2019)
Opposing effects of NPM1wt and NPM1c mutants on AKT signaling in AML
Authors: Zhuo Ren, Mariusz Shrestha, Takashi Sakamoto, Tali Melkman, Li Meng, Rob A. Cairns, Eldad Zacksenhaus, Tak W. Mak, Vuk Stambolic, Mark D. Minden, Jiance Atom Wang
Journal: Leukemia (2019)
A High-Throughput Drug Screen Reveals a Novel Compound Class That Significantly Depletes IRF4 Expression in Multiple Myeloma
Authors: Elizabeth D. Lightbody, Mairead Reidy, Michael P. Agius, Salma El-Behaedi, Romanos Sklavenitis-Pistofidis, Salomon Manier, Irene M. Ghobrial
Journal: Blood (2019)
Activity of the Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Copanlisib, As a Single Agent and in Combination with Carfilzomib in Multiple Myeloma
Authors: Sarah M Larson, Mao Yu Peng, Andrae Vandross, Monica Mead, Zoe Fuchs, Dylan Conklin, Erika Von Euw, Dennis J. Slamon
Journal: Blood (2016)
Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia
Authors: Stephen E Kurtz, Christopher A. Eide, Andy Kaempf, Nicola Long, Anupriya Agarwal, Cristina E. Tognon, Motomi Mori, Brian J. Druker, Jeffrey W. Tyner
Journal: Blood (2019)
Preclinical Evaluation of ALLO-819, an Allogeneic CAR T Cell Therapy Targeting FLT3 for the Treatment of Acute Myeloid Leukemia
Authors: Cesar Sommer, Hsin-Yuan Cheng, Yik Andy Yeung, Duy Nguyen, Janette Sutton, Zea Melton, Julien Valton, Kris Poulsen, Ivana Djuretic, Thomas Van Blarcom, Javier Chaparro-Riggers, Barbra Sasu
Journal: Blood (2019)
GENE-55. GENE EXPRESSION SIGNATURE ASSOCIATED WITH AGGRESSIVE GLIOBLASTOMA GROWTH IS ENRICHED IN CHROMATIN MODIFICATION AND STEMNESS TRANSCRIPTIONAL REGULATION PROGRAMS
Authors: Artem Berezovsky, Oluwademilade Nuga, Yuling Meng, Laila Poisson, Houtan Noushmehr, Ana deCarvalho
Journal: Neuro-Oncology (2019)

Abstract Prognosis of patients diagnosed with IDHwt glioblastoma is influenced by known clinical and demographic factors, and likely by physiological characteristics. Our goal is to determine tumor-intrinsic gene expression signatures associated with aggressive tumor growth in patient-derived xenografts (PDXs). Cancer stem cell (CSC) lines established from 10 IDHwt glioblastoma tumors were implanted orthotopically in cohorts of 10 to 15 nude mice (3x10E5 viable cells/mouse), for development of PDX under uniform conditions. Mice were monitored and sacrificed when symptomatic. Five PDX lines, presenting median survival of 29 to 59 days were classified as short (S) survivors, and 5 lines with median survival between 111 and 134 days as long (L) survivors. RNA was isolated from terminal PDX tumors (n=3/line) and sequenced using Illumina HiSeq 2000. Differential gene expression analysis between tumors in S and L survival groups was conducted using the lmFit and eBayes, and genes were ranked by Benjamini-Hochberg adjusted P-values, set to adj.p&lt; 0.05, resulting in 1663 genes upregulated and 1539 genes downregulated in the aggressive S group. Gene ontology analysis was performed using Metacore (Clarivate Analytics) and Metascape (http://metascape.org). Chromatin modification was significantly enriched in the aggressive tumor group (Metacore, p= 1x 10–12). Remarkably, 40% (654/1663) of the genes upregulated in the aggressive PDX tumors were co-expressed with an epigenetic master regulator in the TCGA glioblastoma RNAseq dataset (cBio Portal, q&lt; 10E-15), and this subset was also highly enriched in chromatin modification, stemness transcriptional regulation and DNA repair (q=10E-45 to q=10E-13). These results indicate that novel host-independent prognostic gene expression signatures can be derived from the PDX models and underline the potential of epigenetic regulators as therapeutic target for aggressive glioblastomas. Our results further indicate that these models are suitable for testing a new generation of epigenetic drugs currently in pre-clinical and clinical development.
SAT0557 OUTPATIENT READMISSION IN RHEUMATOLOGY: A MACHINE LEARNING PREDICTIVE MODEL OF PATIENT’S RETURN TO THE CLINIC
Authors: Luis Rodriguez Rodriguez, Alfredo Madrid García, Judit Font-Urgelles, Dalifer Freites, Cristina Lajas, Esperanza Pato, J Angel Jover, Benjamin Fernandez, Lydia Abasolo
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Readmissions can be defined as the return of a patient to a healthcare setting after a discharged. Attention has been mainly focused on readmissions following inpatient hospitalizations. In the outpatient setting, readmissions have been far less studied. Premature outpatient discharges can have negative impacts at multiple levels, as they may prolong disability, and increase the chance of disease chronification, the demands to the immediate patient's support system, and healthcare resources utilization. As the first step in preventing outpatient readmission, the assessment of the individual patient's risk could be useful to help identify those subjects at greatest risk, so, in a further step we could focus the delivery of an intervention in those patients to reduce their risk. <h3>Objectives:</h3> To develop and validate a machine learning predictive model based on Random Forest, to estimate the risk of readmission in an outpatient rheumatology clinic after discharge (outpatient readmission). <h3>Methods:</h3> Patients stored in a departmental electronic health record from April 1st, 2007 to November 30th, 2016, and followed-up until November 30th, 2017, were included in this study. Only readmissions taking place between 3 and 12 months after discharge were analyzed. Discharge episodes were split into training, validation and test datasets. Clinical and demographic variables, including diagnoses, treatments, quality of life, and comorbidities, were used as predictors. Models were developed using Random Forest in the training dataset, though the combination of several tuning parameters. Models that maximized the area under the receiver operating characteristic curve (ROC-AUC) in the validation set were assessed in the test set. The model with the highest AUC-ROC in the test dataset was considered as the best final model. <h3>Results:</h3> 17,473 patients (18,117 discharges episodes) were analyzed and 1,960 (10.8%) discharges episodes were classified as outpatient readmissions. 48,654 models were finally developed. The best final model showed an AUC-ROC of 0.674 a sensitivity of 0.330 and a specificity of 0.867. The most relevant variables in the model were the number of diagnoses given at discharge, follow-up duration, age, number of previous discharges, previous corticosteroids use and disability. <h3>Conclusion:</h3> We have developed a predictive model for outpatient readmission in a rheumatology setting. Clinical, demographical characteristics as well as medication and disability were the most important predictors. <h3>Disclosure of Interests:</h3> None declared
The Nutrient Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Feasibility Phase
Authors: Laura F. Mendez, Hellen Nguyen, Jenny Nguyen, Alexander Himstead, Melinda R. Lemm, Elena S. Heide, Robyn M. Scherber, Aditi Choudhry, Chelsea O. McKinney, Ruben A. Mesa, Lari Wenzel, Andrew Odegaard, Angela G. Fleischman
Journal: Blood (2019)
Original Versus Generic Lenalidomide in Patients with Relapsed Multipl Myeloma: Comprasion of Effectivity and Adverse Events
Authors: Zahit Bolaman, Sehmus Ertop, Atakan Turgutkaya, Selim Cem, Ayse Hilal Eroglu Kucukerdiler, Birsen Sahip, Irfan Yavasoglu
Journal: Blood (2019)
Implementation of Outpatient High-Dose Cytarabine (HiDAC) for AML: Evaluation of the Impact of Transitioned Outpatient Chemotherapy in an Oncology Care Model Setting
Authors: Leila Jafari, Jubair Hussain, Ravi Krishnadasan, Keri R Maher, Faiz Anwer, Emad Elquza, Christopher Campen, Lauren Sanders, Alyssa Henglefelt, Alicia Ortega, Ali McBride
Journal: Blood (2019)
Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial
Authors: Rosa M. Ayala, Inmaculada Rapado, David Martínez-Cuadron, Esther Onecha, Laura Rufian, Alexandra Juarez, Juan Bergua Burgues, Susana Vives, Jesús Lorenzo Algarra, Mar Tormo, Pilar Martinez, Josefina Serrano, Pilar Herrera, Fernando Ramos, Olga Salamero, Esperanza Lavilla, Cristina Gil, Jose Luis Lopez Lorenzo, Maria-Belen Vidriales, Jorge Labrador, José F. Falantes, Maria Jose Sayas, Bruno Paiva, Eva Barragán, Felipe Prosper, Miguel A. Sanz, Joaquin Martinez Lopez, Pau Montesinos Fernandez
Journal: Blood (2019)
Early Fever Detection By a Novel Wearable Continuous Temperature Monitor in Patients Undergoing Autologous Stem Cell Transplantation
Authors: Jesus Vera-Aguilera, Iman Haji-Abolhassani, Kimary Kulig, Roxana Heitz, Jonas Paludo, Atiyeh Ghoreyshi, Jordan R. Scheevel, Jill M. Schimke, Svetomir N. Markovic
Journal: Blood (2019)
Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission
Authors: H. Moses Murdock, Haesook T. Kim, Bryan Hambley, Pankit Vachhani, Nathan Denlinger, Shannon H. Gier, Christina Cho, Miguel-Angel Perales, John Koreth, Vincent T. Ho, Robert J. Soiffer, Shannon R. McCurdy, Martin Carroll, Sumithira Vasu, Eunice S. Wang, Lukasz P. Gondek, Steven Devine, Edwin P. Alyea, Christopher J. Gibson, R. Coleman Lindsley
Journal: Blood (2019)
IMMU-26. RADIATION AND TEMOZOLOMIDE UP-REGULATES CD70 EXPRESSION AND ENHANCES CAR T- CELL RECOGNITION IN GBM
Authors: Meng Na, Linchun Jin, Haipeng Tao, Alicia Hou, Aida Karachi, Zhiguo Lin, Loic Deleyrolle, Elias Sayour, Duane Mitchell, Jianping Huang
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Glioblastoma (GBM) is a recalcitrant brain cancer in the clinic. The therapeutic effect of using standard care (SC), such as surgery, radiation and/or temozolomide (TMZ) is dismal. CAR T-cell therapy has been increasingly recognized in the field as an innovative therapeutic approach for this malignancy. We identified CD70 as a glioma marker, and show that CD70CAR T cells recognize CD70+ GBMs and mediated regression of established tumors. Since recurrent GBMs that had been heavily treated by the SC treatments expressed a relatively higher level of CD70 than primary tumors, we thus hypothesize that these modalities may help to enhance the expression of CD70 and therapeutic effect of the CD70CAR T cell therapy in GBM. OBJECTIVE To determine if radiation or TMZ treatments could influence the CD70 expression of GBM, and the CD70CAR T-cell recognition. METHODS CD70 expression on GBM cell lines, including primary GBMs (CD70+ or CD70-) and U87 (CD70+), were assessed after treating with escalated doses of irradiation or TMZ. The protein and gene expression were determined by FACS or qRT-PCR analysis, respectively, at 4, 24, 48, and 120 hours post irradiation or TMZ treatment. Tumor recognition post-treatment was also carried out. Paired samples using an RNA-seq dataset from TCGA before and after tumor recurrence were evaluated for the CD70 expression. RESULTS CD70 expression was markedly increased by irradiation or TMZ treatment in a dose-dependent manner (beginning at 24 hours) in vitro in CD70+ GBMs, and a slight increased in the CD70— GBMs. The treatments enhance CD70CAR T cell recognition. Up-regulation of CD70 was found in the paired GBM patients. CONCLUSION This study demonstrates that the irradiation or TMZ treatment significantly up-regulates CD70 expression on GBMs and the CAR-T cell recognition, providing a rationale to combine CD70CAR-T cell therapy with SC for enhanced therapeutic efficacy in GBM.
Rectal and Vaginal Temperatures
Authors: P. M. F. Bishop
Journal: BMJ (1948)

of the minutiae beforehand.That is so of all the sciences, even of mathematics.Finally, 1 did not say that Trotter was a greater man than Francis Bacon, who had in fact anticipated many of hiseviews.The art of tight and lucid compression of thinking was un- known in Bacon's day.And, for me at least, his lovely patches of illuminating thought are imbedded in vast expanses of tedious and repetitive writing.It was Baudelaire who said in a letter to Fraisse on Feb. 2, 1860,